Skip to content
DE

LL-37Endogenous antimicrobial peptide

LL-37 is part of the body’s innate immune system. Its antimicrobial and signalling roles make it scientifically interesting, but administering it is a different question from describing what the body normally produces.

What is LL-37?

LL-37 is a human cathelicidin peptide involved in early immune defence and signalling. It is investigated in infection, inflammation and tissue-repair research.

How it works

It interacts with microbes and human cells. Its inflammatory effects depend on concentration, location and biological context, so it is not uniformly anti-inflammatory.

Effects studied

Antimicrobial activity and local repair

Research includes laboratory systems and wound-surface investigations. 1 2

Evidence: Local or mechanistic findings do not establish systemic benefit for chronic infection, general immunity or recovery.

What does the evidence show?

Mechanistic research and route-specific exploratory studies

More than a miniature antibiotic

LL-37 is a human cathelicidin peptide involved in early defence and immune signalling. It can interact with microbes and with the body’s own cells. These multiple actions help explain why it appears in research on infection, inflammation and tissue repair.

Context can change the effect

An immune signal can help in one tissue or circumstance and contribute to unwanted inflammation in another. LL-37 therefore cannot be described as uniformly anti-inflammatory. Its effects depend on concentration, location and the surrounding biological environment.

Local research is not systemic evidence

Studies involving wound surfaces or laboratory cell systems answer narrower questions than repeated injection into a person. A local healing signal would not establish benefit for chronic infection, general immunity or whole-body recovery. Claims should stay attached to the studied formulation, route and outcome.

What is still needed

To assess LL-37 as a treatment, researchers need evidence on exposure, meaningful benefit, adverse effects and product consistency. Antimicrobial activity must be considered alongside potential immune reactions and unintended inflammatory effects. Its normal biological role provides a reason for research, but cannot replace human treatment data or establish the safety of a product sold for self-administration.

Safety & status

Potential immune reactions and unintended inflammatory effects need assessment. Normal presence in human biology does not establish the safety of repeated administration of a manufactured product.

Country and product status

Country-specific product availability and authorisation require a separate current check.

Frequently asked questions

Is LL-37 always anti-inflammatory?

No. Its effects vary with tissue, concentration and surrounding immune activity.

Can a wound study support systemic injections?

No. Local exposure and healing outcomes cannot establish the safety or benefit of whole-body administration.

Further reading

Concept illustration for LL-37.GuideLL-37: immune function, wound healing and the researchLL-37 is part of innate immunity. What its natural functions and wound-healing research suggest about possible therapeutic uses.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. LL-37 · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
  2. LL-37 · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.